Objective: Distal embolization (DE) during peripheral arterial endovascular interventions is a well-known complication that is poorly studied. The goal of this study was to determine the incidence, risk factors, and effect of DE on the outcomes of lower extremity endovascular interventions (LEIs).
Distal embolization (DE) is a universal phenomenon with endovascular interventions. The reported incidence is variable and depends on how embolization is measured and how aggressively the vascular specialist looks for it. Some recent large clinical trials do not mention DE as a complication, 1 whereas the reported incidence in other case series is as high as 70% to 100%. [2] [3] [4] [5] [6] In one study, Muller et al 5 reported performing 30 lower extremity revascularizations for the femoropopliteal artery and used an embolic protection device (EPD) in all of the cases. All of the filters were found to have debris under microscope examination, and 90% were deemed "clinically significant" because they were visible by the naked eye. 5 Similarly, Lam et al 7 used a transcranial Doppler to detect signals related to DE during superficial femoral artery (SFA) interventions and found 100% occurrence. However, most studies report a low incidence of 1% to 5% that is mostly detected on angiography. [8] [9] [10] The significance of DE depends on the vascular bed treated. Although use of EPDs is considered standard of care during carotid interventions, no societal guidelines are available to direct the use of EPD during lower extremity revascularization. 11 The goal of this study was to determine the incidence of DE during lower extremity endovascular interventions (LEIs) from a large vascular database and assess its effect on outcomes.
METHODS
Database. All LEIs for revascularization in the Vascular Study Group of New England (VSGNE) registry (2010) (2011) (2012) (2013) (2014) were reviewed. The VSGNE registry is a prospective, multicenter, quality improvement program that has been previously described. 12 Variables. Patient demographics, comorbidities, medications, and functional status were analyzed and compared between the two groups. The VSGNE database captures treatment of more than one artery during the same intervention and up to six different arteries. For each artery, up to two different modalities of treatment are captured, including balloon angioplasty, cutting balloon, cryoplasty, self-expanding stent, balloonexpanding stent, covered stent, and atherectomy (orbital, laser, and excisional).
The two groups were also compared with respect to indication for treatment, number of arteries treated, anatomic location of the first artery treated, TransAtlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) classification of the first artery treated, length of the first artery treated, length of occlusion of the first artery treated, and first treatment type. The outcomes examined were technical success, surgical length of stay, procedural mortality, major amputation, and long-term survival. A subgroup analysis focused on characteristics of interventions involving the SFA as the first artery treated in patients with DE and AE. The total length of the artery treated, the total length of the artery occluded, fluoroscopy time, and all treatment types were compared between the two groups. To simplify comparison in interventions for the SFA, the treatment types were pooled as balloon angioplasty (including cryoplasty and use of cutting balloon), stenting (including self-expanding, balloon-expanding, and stent graft), and atherectomy (including orbital, laser, and excisional). Patency of the treated SFA was evaluated. patients with claudication (3.2% vs 1.2%; P < .0001). The incidence of DE was significantly higher in LEIs performed for urgent or emergent conditions compared with elective conditions (elective 1.3% vs urgent 3.3% and emergent 6.4%; P < .001). DE incidence was associated with an increased number of arteries treated during the intervention, as shown with a significantly higher incidence of DE among patients with three or more treated arteries compared with patients with fewer than three treated arteries (3.4% vs 1.5%, respectively; P < .001) and with significantly higher median of number of arteries treated (2 [IQR, [1] [2] [3] 
DISCUSSION
This is the first study of the incidence and significance of DE based on a large multicenter database. The incidence of DE during LEIs is low and varies in the 1% to 2% range. The use of atherectomy devices increases the incidence of DE to 4% to 5%. Treatment for CLI was associated with higher incidence of DE than claudication, and our results are consistent with a recent study that examined the determinants of limb loss and mortality after endovascular revascularization for CLI. The reported incidence of DE was 2.4% and was derived from the VSGNE database for the years 2010 and 2011. 9 This is slightly lower than the incidence among CLI patients but is higher than patients with claudication in our study and is not surprising because patients with CLI have more extensive peripheral artery disease (PAD). Thus, CLI patients are likely to have a higher number of arteries treated and longer total occlusion lengths, which were demonstrated to increase the likelihood of DE in our study as well as in others. 2, 10 In a large case series of 1029 patients, Shrikhande et al 10 reported DE in 1.6%.
Similar to our study, DE did not have a significant effect on patency or limb salvage. All atherectomy modalitiesdorbital, laser, and excisionaldincrease the risk of DE to a similar extent. The concept of atherectomy relies on debulking and reduction of the atheroma burden by vaporization, pulverization, or cutting and removal/aspiration of the plaque. It is far more invasive and manipulative to the vessel wall than balloon angioplasty and stenting, which 10 SilverHawk and Excimer Laser were used to treat 37% of the lesions, and Jetstream and DiamondBack 360 were only used to treat 1.6% of lesions in that particular study. Therefore, it is likely that the differences in DE reflect operator bias and comfort with particular tools and may be related to technical details that are not discussed in that report. Even though we cannot determine from the VSGNE database which particular device was used in each procedure, our results do not support large differences in the incidence of DE with different atherectomy devices. Antiplatelet therapy and statins are the mainstay of medical therapy for patients with PAD. 16 Aspirin decreases the risk of cardiovascular events, cerebrovascular events, and mortality in patients with PAD. 17 Moreover, clopidogrel (the most commonly used P2Y 12 antagonist) has demonstrated an additional benefit compared with aspirin especially in patients with PAD. 18 Statins decrease The database captures detail for each individual artery treated up to six arteries, including TASC II classification, type of treatment, number of lesions, length of occlusion, and treated length. These variables were compared in the two groups only with respect to the first treated artery recorded for each procedure.
the risk of vascular events in patients with PAD regardless of baseline cholesterol level, increase walking distance in claudicant patients, and are associated with decreased amputation. [19] [20] [21] Even though patients in the AE group were more likely to be on antiplatelet and statin therapy, only statins seem to have a protective trend from DE. Yet, a significant number of patients in the database were not on antiplatelet (16.4%) or statins (27.1%). Whether those patients have contraindications, such as bleeding or intolerance to statin, is unclear.
Patients treated emergently are likely to have an element of acute thrombosis associated with atherosclerotic disease that is more likely to dislodge and cause DE. However, the protective effect of age on DE is very small (RR, 0.97) and intriguing but unlikely to be clinically significant.
As eloquently and accurately stated by Dr Allie, "the risk of distal embolization starts with the needle stick and increases with each wire, catheter, balloon, and device manipulation." 22 Yet, there is no consensus on the definition of clinically significant DE during LEIs. The PROTECT (Preventing Lower Extremity Distal Embolization Using Embolic Filter Protection) registry was dedicated to study that phenomenon but had only 40 patients with no comparison group, which made deriving conclusions difficult. 23 Most experts believe that its incidence is low and does not warrant routine use of EPD. However, they recommend selected use of EPD in different highrisk scenarios, such as long occlusions, single-vessel runoff, or concomitantly with atherectomy devices. 22, 24, 25 Although DE did not affect patency and limb loss in our study, it required additional endovascular treatment in most patients and open surgery in 11%. Moreover, patients with DE had longer procedures as reflected by significantly higher fluoroscopy times as well as longer hospital lengths of stay. It is evident that DE is a complication that significantly adds cost and use of resources to LEIs. Selective use of EPD may benefit certain high-risk patient populations. Additional studies are needed to determine the characteristics of that population and the cost-effectiveness of using EPD.
The most important limitation of our study is that DE is self-reported by vascular specialists and lacks a precise definition in the registry. DE is likely underereported, and accounting for that is impossible in this large database. Some specialists may not report a loss of a collateral or a small arterial branch and may consider it clinically not significant, especially in the absence of a consensus definition. Some DE events may be missed by an incomplete final angiogram of the pedal arch. This is dependent on patterns of practice and is not accounted for in the database. Even with recanalization of femoropopliteal total occlusions, some studies 
